Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07660081). This is a study registration, not published results. Lead sponsor: Khyber Medical University Peshawar. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 100 participants (ACTUAL). Conditions: Osteoarthritis, Type 2 Diabetes, Obesity. Interventions: DRUG: Acetyl-l-carnitine; DRUG: Placebo. Primary outcome measures: Serum C-Reactive Protein Concentration , Baseline and Week 12; Fasting Blood Glucose Concentration , Baseline and Week 12; Glycated Hemoglobin (HbA1c) Percentage , Baseline and Week 12; Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) , Baseline and Week 12; Fasting Serum Insulin Concentration , Baseline and Week 12; Serum Leptin Concentration , Baseline and Week 12; Serum Adiponectin Concentration , Baseline and Week 12; Serum Adrenocorticotropic Hormone (ACTH) Concentration , Baseline and Week 12; Serum Malondialdehyde (MDA) Concentration , Baseline and Week 12; Serum Advanced Glycation End Products (AGEs) Concentration , Baseline and Week 12; WOMAC Osteoarthritis Index total Score , Baseline and Week 12; Kellgren-Lawrence Radiographic Grade , Baseline and Week 12. Brief summary: OA is a degenerative bone disease more common in postmenopausal women. Diabetes and obesity are common risk factors for the development of OA. The common symptoms include pain and disability of the affected joint, leading to mobility issues. Acetyl L-carnitine due to its known anti-inflammatory, chondroprotective, and improved insulin-sensitizing effects may help in alleviating the symptoms and progression of OA in obese diabetic postmenopausal women.